We evaluated the role of different CpGs from multiple genes as methylation biomarkers for high-grade cervical intraepithelial neoplasia (CIN).
We suspected that different CpGs assayed by different groups for the same genes may be a major factor contributing to the result variances, and decided to systematically evaluate different CpGs from multiple genes as methylation biomarkers.
With the emergence of epigenetic biomarkers across multiple aspects of breast cancer research, this highlights a potential use for DNA methylation biomarkers as predictors of tamoxifen response with prospective application in neo-adjuvant studies, as discussed previously [ 13].
Circulating DNA methylation biomarkers have also been evaluated.
DNA methylation biomarkers might be promising candidates for this purpose.
Multiple methylation modules exhibit significant enrichment.
They identified digital profiles of aberrant DNA methylation and suggested potential methylation biomarkers for cancer subtypes.
The cutoff points for low levels of methylation can provide 100% specificity for the methylation biomarkers.
Brebi et al. used a genome-wide DNA methylation approach to identify novel methylation biomarkers in cervical cancer.
Also discussed is differential methylation of specific human and viral DNA targets and laboratory methods for measuring methylation biomarkers.
